Why did Vistagen Therapeutics stock crash in December 2025?

Vistagen shares fell more than 80% after the company announced that its PALISADE-3 clinical trial for fasedienol failed to meet the primary efficacy endpoint for treating social anxiety disorder.

What is the Vistagen Therapeutics securities class action about?

The class action alleges that Vistagen may have misled investors about the likelihood of success of its fasedienol clinical program, and that corrective disclosures about trial failure caused substantial investor losses.

What is fasedienol and why was its trial important to investors?

Fasedienol is an experimental treatment for social anxiety disorder and a key asset for Vistagen. Positive trial results were critical to future regulatory approval, valuation, and the company’s long-term growth prospects.

What is the deadline to seek lead plaintiff status in the Vistagen case?

Investors who wish to seek appointment as lead plaintiff in the federal securities class action must file a motion by March 16, 2026, or risk losing the opportunity to represent the class.

Who may be eligible to participate in the Vistagen investor lawsuit?

Investors who purchased Vistagen Therapeutics stock and suffered losses after disclosures about the failed PALISADE-3 trial may be eligible to participate or submit information to counsel.

Vistagen Therapeutics, Inc. - Faruqi & Faruqi LLP

Vistagen Therapeutics, Inc.

Join Action

Case Details

Filed On: January 15, 2026

Ticker VTGN

Class Period 04/01/2024 - 12/16/2025

Lead Plaintiff Deadline 03/16/2026

Days Left to Seek Plaintiff

If you are a Vistagen Therapeutics investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) and reminds investors of the March 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder.

Lead Plaintiff Deadline: March 16, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Vistagen Therapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify